RT Journal Article SR Electronic T1 A Multiomics Approach to Heterogeneity in Alzheimer’s Disease: Focused Review and Roadmap JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19008615 DO 10.1101/19008615 A1 AmanPreet Badhwar A1 G. Peggy McFall A1 Shraddha Sapkota A1 Sandra E. Black A1 Howard Chertkow A1 Simon Duchesne A1 Mario Masellis A1 Liang Li A1 Roger A. Dixon A1 Pierre Bellec YR 2019 UL http://medrxiv.org/content/early/2019/10/10/19008615.abstract AB Etiological and clinical heterogeneity is increasingly recognized as a common characteristic of Alzheimer’s disease and related dementias. This heterogeneity complicates diagnosis, treatment, and the design and testing of new drugs. An important line of research is discovery of multimodal biomarkers that will facilitate the targeting of subpopulations with homogeneous pathophysiological signatures. High-throughput ‘omics’ are unbiased data driven techniques that probe the complex etiology of Alzheimer’s disease from multiple levels (e.g. network, cellular, and molecular) and thereby account for pathophysiological heterogeneity in clinical populations. This review focuses on data reduction analyses that identify complementary disease-relevant perturbations for three omics techniques: neuroimaging-based subtypes, metabolomics-derived metabolite panels, and genomics-related polygenic risk scores. Neuroimaging can track accrued neurodegeneration and other sources of network impairments, metabolomics provides a global small-molecule snapshot that is sensitive to ongoing pathological processes, and genomics characterizes relatively invariant genetic risk factors representing key pathways associated with Alzheimer’s disease. Following this focused review, we present a roadmap for assembling these multiomics measurements into a diagnostic tool highly predictive of individual clinical trajectories, to further the goal of personalized medicine in Alzheimer’s disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis review was performed by members of the Biomarkers Team of the Canadian Consortium on Neurodegeneration in Aging (CCNA; Team Leads: RAD and PB) which is funded by the Canadian Institutes of Health Research (CIHR) and partners. Additional sources of support are as follows. AB is currently supported by a CIHR Postdoctoral Fellowship (funding reference number #152548) and the Courtois Foundation. At the start of the project AB was supported by the Alzheimer Society of Canada Postdoctoral Fellowship. PB is a Research Scholar from the Fonds de recherche du Québec, and is also supported by the Courtois Foundation. SS is supported by the Alzheimer Society of Canada Postdoctoral Fellowship. RAD and GPM are also supported by the U.S. National Institutes of Health (National Institute on Aging, R01 AG008235). SD is a Research Scholar from the Fonds de recherche du Québec - Santué [grant number 30801]. The Consortium d’identification pruécoce de la maladie d’Alzheimer - Quuébec is financed through the Fonds de recherche du Quuébec - Santué / Pfizer Canada Innovation Fund [grant number 25262]. Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableNot applicableAβ or Aβ42amyloid beta or amyloid beta 42APOEapolipoprotein EADNIAlzheimer’s Disease Neuroimaging InitiativeCNcognitively normalFDGfluorodeoxyglucosefMRIfunctional MRIGWASgenome-wide association studieslvPPAlogopenic progressive aphasiaMAFminor allele frequencyMCImild cognitive impairmentNDDsneurodegenerative diseasesNGSnext-generation genome sequencingPCAposterior cortical atrophyPETpositron emission tomographyPRSpolygenic risk scoreSNPssingle nucleotide polymorphisms